The Cutter Polio Vaccine Incident

Background

Polio epidemics frightened families and left thousands dead or disabled each year. A vast field trial found Jonas Salk's killed-virus vaccine effective, and authorities announced results and licensed several manufacturers on 12 April. Public demand and an unprecedented national rollout compressed the time available for regulatory review and production learning.

What happened

Cutter followed the licensed process, but viral clumping and tissue debris could shield poliovirus from formaldehyde. Safety sampling did not reliably detect surviving virus in released lots. Reports of paralysis appeared within days, clustered along nerves of the injected limb, and epidemiologists connected cases to Cutter product.

Aftermath

The government recalled Cutter vaccine and paused the national program while investigators traced lots and contacts. Fear reduced public confidence, but revised testing allowed vaccination to resume. Because vaccine-derived virus spread to close contacts, the event produced more cases than those directly injected and required unusually careful epidemiologic attribution.

Long-term consequences

Federal oversight became more prescriptive, with strengthened inactivation standards, testing, inspections, and authority that later informed modern biologics regulation. Litigation established manufacturer liability even without conventional negligence, influencing product-liability law. The safer program ultimately prevented vastly more polio than the incident caused.

Significance

Cutter is essential to vaccine history because acknowledging a real manufacturing failure strengthens, rather than weakens, the case for rigorous vaccination systems. A successful scientific principle still requires validated industrial process, surveillance, transparent recall, and independent regulation.

What remains today

Former Berkeley industrial sites, court records, lot investigations, epidemiologic papers, regulatory archives, and survivor histories preserve the incident. Modern biologics manufacturing controls are its most consequential, if largely invisible, material legacy.

Uncertainty

Published totals differ by whether cases among vaccinees, household contacts, community contacts, nonparalytic infections, and later diagnoses are combined. The commonly cited figures are estimates from epidemiologic reconstruction. The incident involved specific Cutter lots, not every Salk vaccine.